INGELHEIM, Germany & DAIX, France - Tuesday, May 31st 2016 [ME NewsWire]
New collaboration to harness the therapeutic potential of a promising novel target for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
Total deal value up to €170 million, plus tiered sales royalties
(BUSINESS WIRE)-- Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-year research and drug discovery collaboration and licensing agreement.
Under the terms of the agreement, the Inventiva and Boehringer Ingelheim research teams will jointly validate a new therapeutic concept with the aim of discovering new medicines for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva’s deep knowhow and proprietary technologies in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s capabilities in drug discovery and clinical development of new therapeutic agents.
The new collaboration is an example of Boehringer Ingelheim’s increasing focus on external innovation and builds on the company’s track record in IPF drug development. Boehringer Ingelheim has successfully developed nintedanib (OFEV®), a small molecule tyrosine kinase inhibitor, approved and marketed globally for the treatment of IPF in adults and will be responsible for clinical development and commercialization of potential drug candidates from the collaboration.
IPF is a debilitating and fatal lung disease with high mortality, affecting as many as 3 million people worldwide. It is characterized by chronic scaring and remodeling of the lung and progressive decline in lung function. IPF is the most common interstitial lung disease encountered worldwide and poses a major public health threat, as 70% to 80% of patients die within only 5 years from the diagnosis. To date, the cause of IPF is unidentified and despite recent progress treatment options for patients are still limited.
“We are very proud to enter into this collaboration with Boehringer Ingelheim, a company well-reputed for its excellent research and development skills in the field of fibrosis, and particularly Idiopathic Pulmonary Fibrosis,” commented Inventiva’s co-founder and CSO Pierre Broqua. We plan, alongside developing our own pipeline, on pursuing our strategy of establishing collaborative research partnerships with the world’s biggest pharmaceutical companies. This new partnership further testifies to Inventiva’s expertise and contributes to strengthening our position as a leading and innovative actor in the field of fibrosis.”
“We are enthusiastic about this partnership and look forward to collaborating with Inventiva’s team to develop a potential new breakthrough therapy for the treatment of Idiopathic Pulmonary Fibrosis,” concluded Clive R. Wood, Ph.D., Senior Corporate Vice President Discovery Research at Boehringer Ingelheim. “We are impressed by Inventiva’s research and drug discovery competencies and deep knowledge of the field. We firmly believe that joining forces with Inventiva will enable us to foster translation of an aspirational new therapeutic concept into eagerly awaited new therapies for patients.”
Inventiva will receive an upfront payment and is eligible to receive research funding, potential research, development, regulatory and commercial milestone payments of up to €170 million and tiered royalties on net sales of the products resulting from the partnership. Full financial details remain undisclosed.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-inventiva-collaborate-develop
Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Director Corporate Communications
Tel. +49 (6132) 77-90815
press@boehringer-ingelheim.com
or
Inventiva
Frederic Cren
Chief Executive Officer
Tel: +33 (0)3 80 44 75 00
info@inventivapharma.com
or
NewCap
Press Relations
Nicolas Merigeau / Arthur Rouillé
Tel: +33 (0) 1 44 71 94 98 / +33 (0)1 44 71 98 51
inventiva@newcap.eu
Permalink: http://www.me-newswire.net/news/18042/en
After years of working in construction and smoking cigarettes,I was diagnosed with COPD and pulmonary fibrosis, i started on COPD/IPF Herbal formula treatment from multivitamin herbal cure, the treatment worked incredibly for my lungs condition. I used the herbal treatment for over 7 weeks, it reversed my chronic obstructive pulmonary disease. My severe shortness of breath, dry cough, low energy, fatigue, chest tightness and others gradually disappeared. Visit multivitamin herbal cure official web page multivitamincare.org This COPD and pulmonary fibrosis treatment has improved the quality of my life greatly, i breath much better and It feels comfortable!
ReplyDelete